Samah Al Kharji

#AFib #الرجفان_الاذيني

TP-segment downsloping on ECG strongly suggests: A. Hyperkalemia B. Acute pericarditis C. Posterior MI D. LV aneurysm

🫀💊 Lipid management after statins: more tools, more complexity, more responsibility This 2025 JACC Advances expert panel offers a timely, pragmatic appraisal of lipid management in the post-statin era, comparing international guidelines and translating them into real-world, case-based decisions . 📌 Core message LDL-C remains causal for ASCVD, but the therapeutic landscape has expanded dramatically. Statins are still the foundation, yet non-statin therapies are now essential to reach modern LDL-C targets—especially in high- and very-high-risk patients. 🌍 Guidelines: same evidence, different philosophies ESC guidelines are the most aggressive (LDL-C <55 mg/dL, and <40 mg/dL after recurrent events). ACC/AHA remain more conservative, prioritizing randomized trial evidence. Canadian guidelines sit in between.The result? Different thresholds, same patients, increasing clinical ambiguity. 🧠 Key advances highlighted Combination therapy beats dose escalation: doubling statins yields ~6% LDL-C reduction, while adding ezetimibe, PCSK9 inhibitors, bempedoic acid or inclisiran achieves 20–60%. Therapeutic inertia is a major problem—many high-risk patients remain far above target. Imaging matters: CAC ≥300 AU confers a risk similar to secondary prevention and should trigger aggressive LDL-C lowering. Lp(a) and ApoB deserve broader screening, even if outcome-driven targets are still evolving. 👩‍⚕️ Why the case-based approach matters Real patients rarely fit guideline boxes: young adults, women planning pregnancy, South Asian populations, HIV patients, severe hypertriglyceridemia. The paper shows how rigid guideline application fails without clinical judgment. 🔮 Bottom line We are no longer in a “statin-only” world. Modern lipid management requires earlier risk detection, imaging-guided stratification, combination therapy, and individualized targets. Guidelines inform decisions—but expertise personalizes them 🚀

📣EHRA Document 📚 #Europace Afib management by targeting comorbidities and reducing AF burden: the 10th AFNET/EHRA consensus conference just published 🚀 🌐academic.oup.com/europace/artic… @EHRAPresident @GiulioConte9 @Dominik_Linz @AndyZhangMD @FraSantoroMD @DavideMei93 @marcovitoloMD

Video: Interview with Dr. Samah Alkharji – Discussion About arrhythmia On Good Morning Kuwait show KTV 2 alziadiq8.com/524315.html

Great pleasure to join today’s LBBAP webinar and share practical insights on optimal tools and real-world implantation techniques. Honored to be part of an excellent faculty and thankful to the organizers for this valuable educational program. Always happy to contribute to advancing conduction system pacing. @curilakarol @DFahadAlmehmadi @1sinusrhythm @Medtronic

Occupational hazards in cardiac electrophysiology: Insights from an HRS member survey heartrhythmjournal.com/article/S1547-…

🚨#Europace #Epeeps VT ablation vs. anti-arrhythmic drug : a meta-analysis of RCTs ✍️@FraSantoroMD et al. from @DASCAMaastricht #EHRA Course @GiulioConte9 @marcovitoloMD @AndyZhangMD @Dominik_Linz @DavideMei93 @ESC_Journals @LuigiDiBiaseMD @EHRAPresident

Timing of stroke risk reassessment in atrial fibrillation patients with a CHA2DS2-VA score of 0 or 1: the Norwegian AFNOR study New risk factors emerged in half of AF patients within 1.7 years. Age-specific differences underscore the need for tailored reassessment, suggesting a shorter interval of 6 months for patients ≥55 years and 1 year for those <55 years and routinely at age 65 and 75 years. #Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare @DrMarthaGulati @hvanspall @Hragy @biljana_parapid @AnastasiaSMihai @ESC_Journals @escardio academic.oup.com/europace/artic…

#EHRAtopicweek on Sustainability in EP ✅ Reusing pacemakers and catheters is: 🩺 Safe — The recent Europace #EHRA_ESC Young EP survey found that over two-thirds (67.8%) of EPs have used reprocessed materials, most viewing them as safe and cost-effective. Published studies show complication rates below 1% when reuse follows validated protocols ⚖️ Ethical — Reprocessing helps make EP procedures available to more patients, especially in regions with limited access ♻️ Sustainable — Reuse reduces costs and environmental impact by cutting waste and conserving high-value materials 🔗 bit.ly/3J2zCoU

fresh online ⚡️❄️ 🔥 ->🫀📈🧠📉 Peri-procedure and Mid-Long Term Effects of Pulsed Field Ablation vs. Thermal Ablation (Cryo- or Radiofrequency) on Autonomic Nervous System Function in Atrial Fibrillation: A Systematic and Quantitative Pooled-Analysis with Potential Implications for Patient Selection (The PULSE-COLD-HEAT-ANS Collaboration) academic.oup.com/europace/artic… @EuropaceEiC @ESC_Journals @escardio @DGK_org @AGEP_DGK @S_NarayanMD @C_Meyer_MD @Dominik_Linz @AndreasRillig @LauraPerrottaEP @KarsNeven @ChristianHeeger @MRuwald @ftrae @BA_Mulder @purerfellner @EHRAPresident @SergeBoveda @jongichun @ShaojieChen1 thank you ALL

Spot the Clue: What do you see in the ECG? Challenge your colleague! ow.ly/UjeM50WY71U A. Sinus rhythm with bigeminy premature ventricular complexes (PVC) B. Sinus rhythm, high grade atrioventricular (AV) block with PVC C. Sinus rhythm, premature atrial complex (PAC) with aberrant ventricular conduction D. Sinus pause following PVC E. Sinus bradycardia, second degree Mobitz 1 AV block, interpolated bigeminy PVCs #EHJCaseReports @Phiso_de @TJ_Yeo @aayshacader @BoldiKovacsMD @sukritibanthiya @ANazmiCalik @O_Azizy_MD @saramoscatelli7 @EHJCREiC #CardioX #EPeeps

#UseHeart to take action and demand our leaders make heart health a priority this #WorldHeartDay. ❤️ Say YES to healthier hearts everywhere: worldheartday.org/petition. #HeartYes world-heart-federation.org/world-heart-da…

Join us at the 17th Gulf Heart Association Conference on November 20-22 in Doha, Qatar! Register using : invt.io/1txbepie0rf

📢 New publication in ESC Heart Failure: "Epicardial, visceral and subcutaneous adipose tissue in heart failure with preserved ejection fraction". 👉 ow.ly/hOsK50WNnqy #HFpEF #HeartFailure #ESCHeartFailure #HFA_ESC @EJHFEiC @JanBiegus @Ppponikowski @hvanspall @ShelleyZieroth @FudimMarat @gcfmd @AlexMebazaa @MarcoMetra @GianluSava

WITHDRAW-AF RCT 📌 In👫w/ presumed AF-induced #cardiomyopathy & normalized #LVEF after SR restoration 👉 withdrawal of #HF therapy is not assoc w/ LVEF ⬇️ again in 90% of👫in the following 6-m #EPeeps #afib #HeartFailure #CardioTwitter #MedTwitter @DrMarthaGulati @JagSinghMD

My Takeaways from #ESCCongress2025 #LBCT Followed remotely, Thnx to those who spread this huge knowledge globally🫀#ESCCongress #ESC2025 #CardioEd

@javadm20 Agree I dont think all HFrEF should be dealt with the same way. LBBAP made us shift from just CS implant and hope for device optimization to really find the optimal physiological and anatomical target which is also variable by phenotype

2negative trial surprised me! CAAN AF and PhysioSync HF! #Epeeps #ESC2025

From the latest 2025 #ESCGuidelines for the management of #CVdisease in pregnancy: 💊Choices of medications use during Pregnancy & during lactation+breastfeeding Full paper @ehj_ed #EHJ: doi.org/10.1093/eurhea… @escardio @ESC_Journals #ESCCongress @CardioOb #CardioObstetrics

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy: @NEJM #ESCCongress2025 🥸 Aficamten for HOCM 😱 Summary 👇👇👇